ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On August3, 2017, Acceleron Pharma Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended June30, 2017. A copy of the press release is furnished as Exhibit99.1 hereto.
The information contained in this Item, including Exhibit99.1 attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
DescriptionofExhibit |
|
99.1 |
Press release of Acceleron Pharma Inc. dated August 3, 2017 |
ACCELERON PHARMA INC ExhibitEX-99.1 2 xlrn-20170803ex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results- Completed full enrollment of luspatercept MEDALIST and BELIEVE Phase 3 trials – - Presented updated luspatercept Phase 2 results in patients with MDS and beta-thalassemiareceiving treatment for up to two years — Treated first patient in ACE-083 Phase 2 study in Charcot-Marie-Tooth disease — Upcoming R&D Day on September 19th to highlight Acceleron’s pipeline and strategic focus -Cambridge,…To view the full exhibit click here
About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.
